Eton Pharmaceutcials
ETON
10 hedge funds and large institutions have $14M invested in Eton Pharmaceutcials in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 3 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
16% more capital invested
Capital invested by funds: $12M → $14M (+$1.96M)
1.51% more ownership
Funds ownership: 8.51% → 10.03% (+1.5%)
17% less funds holding
Funds holding: 12 → 10 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.41M |
| 2 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$176K |
| 3 |
PCM
Prelude Capital Management
New York
|
+$148K |
| 4 |
BlackRock
New York
|
+$131K |
| 5 |
Morgan Stanley
New York
|
+$17.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AMH
Apollo Management Holdings
New York
|
-$720K |
| 2 |
Barclays
London,
United Kingdom
|
-$70K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$57.1K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $8.49M | +$2.41M | +310,227 | +41% |
|
|
AIC
2
AWM Investment Company
New York
| $3.36M | – | – | – |
|
|
DC
3
Diametric Capital
Boston,
Massachusetts
| $1.14M | +$176K | +22,620 | +19% |
|
|
PCM
4
Prelude Capital Management
New York
| $442K | +$148K | +19,072 | +52% |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $227K | +$14K | +1,800 | +7% |
|
|
6
BlackRock
New York
| $206K | +$131K | +16,813 | +181% |
|
7
Wells Fargo
San Francisco,
California
| $47K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $25K | +$13.4K | +1,728 | +122% |
|
|
9
Morgan Stanley
New York
| $18K | +$17.6K | +2,264 | New |
|
|
10
UBS Group
Zurich,
Switzerland
| $9K | -$57.1K | -7,353 | -86% |
|
|
AMH
11
Apollo Management Holdings
New York
| – | -$720K | -90,000 | Closed |
|
|
12
Barclays
London,
United Kingdom
| – | -$70K | -8,800 | Closed |
|
|
13
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$12K | -1,621 | Closed |
|
ETON Hedge Fund Activity: Q2 2019 in Review
10 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Eton Pharmaceutcials (ETON) for Q2 2019, worth a combined $14M — up 16% from $12M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ETON and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was Opaleye Management, adding an estimated $2.41M. The largest seller was Apollo Management Holdings, exiting entirely with an estimated $720K sold.
- 10 institutional investors held Eton Pharmaceutcials (ETON) as of Q2 2019, down from 12 in Q1 2019.
- Funds reported $14M of Eton Pharmaceutcials stock for Q2 2019, up 16% quarter-over-quarter.
- 1 fund opened new Eton Pharmaceutcials positions in Q2 2019 and 3 closed out, a net change of -2 holders.
- The largest Eton Pharmaceutcials buyer in Q2 2019 was Opaleye Management, an estimated $2.41M added.
- The largest Eton Pharmaceutcials seller in Q2 2019 was Apollo Management Holdings, an estimated $720K sold.
Based on aggregated 13F filings for Q2 2019.